GTx-104 FDA CRL Pinpoints Manufacturing Issues, Not Clinical; Phase 3 Data Positive
GRCE sits 25% above its 52-week low of $1.79 on elevated volume (5.1× avg).
Summary
Grace Therapeutics has updated its corporate presentation, providing critical details regarding the FDA's Complete Response Letter (CRL) for its lead drug candidate, GTx-104. The CRL specifically cited CMC and manufacturing readiness issues, explicitly stating that no clinical deficiencies were identified. This update also revealed positive Phase 3 STRIVE-ON trial data, demonstrating clinical and pharmacoeconomic benefits. This news follows the initial announcement of the FDA's decision on April 23, which was reported by Reuters and an 8-K filing. The clarification that the CRL is due to manufacturing rather than clinical concerns, coupled with strong Phase 3 data, significantly mitigates the initial negative impact and provides a clear path forward for the drug. The company plans to request a Type A meeting with the FDA and resubmit the NDA once manufacturing issues are resolved, which will be a key catalyst to watch.
At the time of this announcement, GRCE was trading at $2.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.6M. The 52-week trading range was $1.79 to $5.18. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.